Stock KLAR KLARIA PHARMA HOLDING AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Klaria Pharma Holding AB

Equities

KLAR

SE0007280326

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:47 2024-05-10 EDT 		5-day change 1st Jan Change
0.391 SEK +30.33% Intraday chart for Klaria Pharma Holding AB +22.57% -15.37%
02-29 Klaria Pharma Holding AB (publ.) Reports Earnings Results for the Full Year Ended December 31, 2023 CI
02-29 Klaria Pharma Holding AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's enterprise value to sales, at 7.56 times its current sales, is high.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
KLARIA PHARMA HOLDING AB Stock Klaria Pharma Holding AB
-15.37% 2.94M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+3.91% 108B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.87% 104B
B+
ARGENX SE Stock argenx SE
+1.28% 22.33B
B
BIONTECH SE Stock BioNTech SE
-13.14% 22.19B
B+
GENMAB A/S Stock Genmab A/S
-7.05% 18.69B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.36% 17.74B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.66% 17.64B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.75% 14.05B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.70% 12.51B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
  1. Stock Market
  2. Equities
  3. KLAR Stock
  4. Ratings Klaria Pharma Holding AB
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW